
Two to three weeks after treatment, the previously paralyzed mice began to walk. Credit: Lehrstuhl für Zellphysiologie
To date, paralysis resulting from spinal cord damage has been irreparable. With a new therapeutic approach, scientists from the Department for Cell Physiology at Ruhr-Universität Bochum (RUB) headed by Professor Dietmar Fischer have succeeded for the first time in getting paralyzed mice to walk again. The keys to this are the protein hyper-interleukin-6, which stimulates nerve cells to regenerate, and the way how it is supplied to the animals. The researchers published their report in the Journal Nature Communications from 15 January 2021.
When the communication breaks down
Spinal cord injuries caused by sports or traffic accidents often result in permanent disabilities such as paraplegia. This is caused by damage to nerve fibers, so-called axons, which carry information from the brain to the muscles and back from the skin and muscles. If these fibers are damaged due to injury or illness, this communication is interrupted. Since severed axons in the spinal cord can’t grow back, the patients suffer from paralysis and numbness for life. To date, there are still no treatment options that could restore the lost functions in affected patients.
Designer protein stimulates regeneration
In their search for potential therapeutic approaches, the Bochum team has been working with the protein hyper-interleukin-6. “This is a so-called designer cytokine, which means it doesn’t occur like this in nature and has to be produced using genetic engineering,” explains Dietmar Fischer. His research group already demonstrated in a previous study that hIL-6 can efficiently stimulate the regeneration of nerve cells in the visual system.
In their current study, the Bochum team induced nerve cells of the motor-sensory cortex to produce hyper-Interleukin-6 themselves. For this purpose, they used viruses suitable for gene therapy, which they injected into an easily accessible brain area. There, the viruses deliver the blueprint for the production of the protein to specific nerve cells, so-called motoneurons. Since these cells are also linked via axonal side branches to other nerve cells in other brain areas that are important for movement processes such as walking, the hyper-interleukin-6 was also transported directly to these otherwise difficult to access essential nerve cells and released there in a controlled manner.
Applied in one area, effective in several areas
“Thus, gene therapy treatment of only a few nerve cells stimulated the axonal regeneration of various nerve cells in the brain and several motor tracts in the spinal cord simultaneously,” points out Dietmar Fischer. “Ultimately, this enabled the previously paralyzed animals that received this treatment to start walking after two to three weeks. This came as a great surprise to us at the beginning, as it had never been shown to be possible before after full paraplegia.”
The research team is now investigating to what extent this or similar approaches can be combined with other measures to optimize the administration of hyper-Interleukin-6 further and achieve additional functional improvements. They are also exploring whether hyper-interleukin-6 still has positive effects in mice, even if the injury occurred several weeks previously. “This aspect would be particularly relevant for application in humans,” stresses Fischer. “We are now breaking new scientific ground. These further experiments will show, among other things, whether it will be possible to transfer these new approaches to humans in the future.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Gene therapy
- Gene Therapy: Get ready for the weaponization olympics
William Barr took another spin through the news cycle last week, and though it wasn’t anywhere near as uplifting as his star turn before the Jan. 6 committee, you can be sure he came out wearing the ...
- UniQure nabs another gene therapy for ALS
For $10 million up front, UniQure has licensed rights to its second experimental treatment for the condition, a medicine from startup Apic Bio that should enter human testing later this year.
- MD gene therapy invented at Nationwide Children's could hit $4B annual sales if approved
If approved, a gene therapy for a fatal form of muscular dystrophy could generate $4 billion in sales annually, according to the biopharmaceutical company that licenses the technology from Nationwide ...
- Cell and Gene Therapy Market 2023 | Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2028
Get a Sample Report "Cell and Gene Therapy Market" to 2028 at- The report offers in-depth assessment of the growth and other aspects of the Cell and Gene Therapy Market in important regions. Key ...
- A startup launches with plans to open up a gene and cell therapy bottleneck
T therapies and ex vivo gene therapies has swelled in recent years, but manufacturing hasn’t been able to keep up with demand.
Go deeper with Google Headlines on:
Gene therapy
[google_news title=”” keyword=”gene therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Designer cytokine
- Scientists develop new design principles to improve cancer vaccine structure
Researchers at Northwestern University International Institute for Nanotechnology IIN have discovered a novel method to significantly boost the effectivenes ...
- Transforming the way cancer vaccines are designed and made
A new way to significantly increase the potency of almost any vaccine has been developed. The scientists used chemistry and nanotechnology to change the structural location of adjuvants and antigens ...
- What’s Holding Cell Therapies Back? A Look Into The Evolution And Future Of Stem Cell Tech
While cell therapies have already come a long way, there is much to be done to streamline clinical trial submissions and approvals.
- Researchers create the first 'living medicine' to treat drug-resistant lung infections
Researchers have designed the first 'living medicine' to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria which is naturally resistant to many types of ...
- 'Living medicine' created to tackle drug-resistant lung infections
Researchers have designed the first "living medicine" to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria that is naturally resistant to many types of ...
Go deeper with Google Headlines on:
Designer cytokine
[google_news title=”” keyword=”designer cytokine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]